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Background
GLP-1 peptide is an endogenous insulinotropic peptide.
GLP-1 receptors are expressed throughout the brains of
rodents and humans. Intracerebroventricular GLP-1
administration reduced the levels of amyloid-beta peptide
(Aβ) in diabetic mice and protected cultured hippocam-
pal neurons against Aβ and iron induced stress suggesting
that GLP-1 can modify amyloid precursor protein (APP)
processing and protect against oxidative injury [1]. In the
double transgenic mice model associated with early-onset
AD, the effect of GLP-1 secreting human mesenchymal
stem cells (hMSC) on A-β40/42 load, Aβ associated gliosis
and microglial response were investigated in the present
study.
Materials and methods
Alginate microcapsules (CellBeads®) containing "native"
(CB085) or GLP-1 transfected hMSCs (CB087) were ster-
eotactically implanted into the right ventricle of double
transgenic mice mutant expressing APP and presenelin-1
protein (APPswe, PSEN1dEG; JACKSON LAB) at 27 weeks
of age (n = 14 each). After 8 weeks of implantation (i.e. 35
weeks of age), brains of 4 animals per group were proc-
essed for histological assessment using Antibodies against
Aβ40/42 (polyclonal; US BIOLOGICAL), glial fibrillary
acidic protein (GFAP polyclonal, DAKO) and the micro-
glial marker CD11b (monoclonal; BIOMOL). The
remaining brains were used for Aβ40/42 ELIZA. N= 7 35-
36 weeks old Tg-mice provided the age-matched early-
onset AD controls.
Results
Total counts of Aβ40/42 positively stained plaques
assessed in the frontal cortex were reduced in the animals
with GLP-1 transfected CellBeads® implants when com-
pared to the "native" stem-cell group and the control:107
± 24 (GLP-1 hMSCs) vs. 165 ± 44 ("native" hMSCs) vs.
140 (control, n = 1); p = 0.07 (t-test of GLP-1 vs. "native"
hMSCs). Likewise, the number of reactive astrocytes (>
three GFAP positively stained processes) measured in the
dentate gyrus of the hippocampus showed a tendency
towards a lower count in GLP-1 CellBeads® mice. Morpho-
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metric analysis of CD11b positively stained particles per
cortical area (%) showed most striking evidence in group
differences: animals with GLP-1 transfected CellBeads®
showed a significant reduction of microglial immunore-
activity against age-matched AD control: 0.28 ± 0.14% vs.
0.58 ± 0.05% (p = 0.02, t-test). "Native" CellBeads®
showed a reduced but not significant change in the micro-
glial response.
Conclusion
GLP-1 producing stem cells encapsulated in alginate have
lowered Aβ40/42 load in a mouse model of early-onset
AD, which corresponded to a significant down-regulation
of specific microglial-type changes in that model.
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